A C-terminal amino acid substitution in the γ-chain caused by a novel heterozygous frameshift mutation (Fibrinogen Matsumoto VII) results in hypofibrinogenaemia

Summary

We found a novel hypofibrinogenemia designated as Matsumoto VII (M-VII), which is caused by a heterozygous nucleotide deletion at position g.7651 in FGG and a subsequent frameshift mutation in codon 387 of the γ-chain. This frameshift results in 25 amino acid substitutions, late termination of translation with elongation by 15 amino acids, and the introduction of a canonical glycosylation site. Western blot analysis of the patient’s plasma fibrinogen visualised with anti-γ-chain antibody revealed the presence of two extra bands. To identify the extra bands and determine which of the above-mentioned alterations caused the assembly and/or secretion defects in the patient, 11 variant vectors that introduced mutations into the cDNA of the γ-chain or γ′-chain were transfected into Chinese hamster ovary cells. In vitro expression of transfectants containing γΔ7651A and γΔ7651A/399T (γΔ7651A with an amino acid substitution of 399Asn by Thr and a variant lacking the canonical glycosylation site) demonstrated a reduction in secretion to approximately 20% of the level seen in the transfectants carrying the normal γ-chain. Furthermore, results from other transfectants demonstrated that eight aberrant residues between 391 and 398 of the M-VII variant, rather than the 15 amino acid extension or the additional glycosylation, are responsible for the reduced levels of assembly and secretion of M-VII variant fibrinogen. Finally, the results of this study and our previous reports demonstrate that the fibrinogen γ-chain C-terminal tail (388–411) is not necessary for protein assembly or secretion, but the aberrant amino acid sequence observed in the M-VII variant (especially 391–398) disturbs these functions.

Keywords

Hypofibrinogenaemia - nucleotide deletion - frameshift mutation - assembly - secretion

• References

• 1 Doolittle RF, Bouma IH, Cottrell BA. et al. The covalent structure of human fibrinogen. In: Bing DH, ed. The chemistry and physiology of the human plasma proteins. New York, NY: Pergamon Press 1979; pp. 77-95.
• 2 Doolittle RF. Fibrinogen and fibrin. Sci Amer 1981; 245: 92-101.
• 3 Kant JA, Fornace Jr. AJ, Saxe D. et al. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 1985; 82: 2344-2348.
• 4 Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: evidence for an extended carboxyterminal sequence in a normal gamma chain variant (γ’). Proc Natl Acad Sci USA 1980; 77: 5069-5073.
• 5 Chung DW, Davie EW. γ and γ’ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984; 23: 4232-4236.
• 6 Terasawa F, Okumura N, Kitano K. et al. Hypofibrinogenemia associated with a heterozygous missense mutation γ153Cys to Arg (Matsumoto IV): In vitro expression demonstrates defective secretion of the variant fibrinogen. Blood 1999; 94: 4122-4131.
• 7 Okumura N, Terasawa F, Tanaka H. et al. Analysis of fibrinogen γ-chain truncations shows the C-terminus, particularly γIle387, is essential for assembly and secretion of this multichain protein. Blood 2002; 99: 3654-3660.
• 8 Kani S, Terasawa F, Yamauchi K. et al. Analysis of fibrinogen variants at γ387Ile shows that side-chain of ?387 and the tertiary structure of γC terminal tail are important for not only assembly and secretion of fibrinogen but also lateral aggregation of protofibrils and XIIIa-catalyzed γ-γ dimer formation. Blood 2006; 108: 1887-1894.
• 9 Okumura N, Terasawa F, Hirota-Kawadobora M. et al. A novel variant fibrinogen, deletion of Bbeta111Ser in coiledcoil region, affecting fibrin lateral aggregation. Clin Chim Acta 2006; 365: 160-167.
• 10 Okumura N, Gorkun OV, Lord ST. Severely impaired polymerization of recom-binant fibrinogen γ-364 Asp His, the substitution discovered in a heterozygous individual. J Biol Chem 1997; 272: 29596-29601.
• 11 Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation. Clot retraction dose not require an intact fibrinogen γ chain C terminus. J Biol Chem 1996; 271: 8553-8555.
• 12 Binnie CG, Hettasch JM, Strickland E. et al. Characterization of purified recombinant fibrinogen: partial phosphorylation of fibrinopeptide A. Biochemistry 1993; 32: 107-113.
• 13 Kudryk B, Rohoza A, Ahadi M. et al. Antibodies specific for neoantigens expressed on chains or degradation products of fibrin(ogen). In: Fibrinogen 3 -Biochemistry, biological functions, gene regulation and expression. Amsterdam: Elsevier Science Publishers BV. 1988: 129-132. pp
• 14 Lovely RS, Falls LA, Al-Mondhiry HA. et al. Association of γA/γ’ fibrinogen levels and coronary artery disease. Thromb Haemost 2002; 88: 26-31.
• 15 Duga S, Asselta R, Santagostino E. et al. Missense mutations in the human fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Thromb Haemost 2002; 88: 26-31.
• 16 Brennan SO, Wyatt J, Medicina D. et al. Fibrinogen Brescia. Hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a γ284 Gly→Arg mutation. Am J Pathol 2000; 157: 189-196.
• 17 Kani S, Terasawa F, Lord ST. et al. In vitro expression demonstrates impaired secretion of the γAsn319,Asp320 deletion variant fibrinogen. Thromb Haemost 2005; 94: 53-59.
• 18 Yee VC, Pratt KP, Cote HCF. et al. Crystal structure of a 30 kDa C-terminal fragment from γ-chain of human fibrinogen. Structure 1997; 05: 125-138.
• 19 Spraggon G, Everse SJ, Dollittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 1997; 389: 455-462.
• 20 Donahue JP, Patel H, Anderson WF. et al. Three-dimensional structure of the platelet integrin recognition segment of the fibrinogen γ chain obtained by carrier protein-driven crystallization. Proc Natl Acad Sci USA 1994; 91: 12178-12182.
• 21 Mayo KH, Burke C, Lindon JN. et al. 1H NMR sequential assignments and secondary structure analysis of human fibrinogen γ-chain C-terminal residues 385–411. Biochemistry 1990; 29: 3277-3286.
• 22 Blumenstein M, Matsueda GR, Timmons S. et al. A -turn is present in the 392–411 segment of the human fibrinogen γ-chain. Effects of structural changes in this segment on affinity to antibody 4A5. Biochemistry 1992; 31: 10692-10698.
• 23 Vu D, Di Sanza C, Caille D. et al. Quality control of fibrinogen secretion in the molecular pathogenesis of congenital afibrinogenemia. Hum Mol Genet 2005; 14: 3271-3280.
• 24 Sugo T, Nakamikawa C, Yoshida N. et al. End-linked homodimers in fibrinogen Osaka VI with a B-chain extension lead to fragile clot structure. Blood 2000; 96: 3779-3785.
• 25 Lefebvre P, Velasco PT, Dear A. et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen A IVS4+1G>T mutation and an AαGln328 truncation (fibrinogen Keokuk). Blood 2004; 103: 2571-2576.